References

Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper

10.1111/all.13599 · 2019 · External reference

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice

10.1136/bmj.328.7437.434 · 2004 · External reference

Respiratory hypersensitivity reactions to NSAIDs in Europe: the global allergy and asthma network (GA(2) LEN) survey

10.1111/all.12941 · 2016 · External reference

NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs

10.1038/s41598-018-34668-1 · 2018 · External reference

Evaluation of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs according to the latest classification

10.1111/all.12689 · 2015 · External reference

Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO statement

10.1016/j.waojou.2025.101086 · 2025 · External reference

Aeroallergen sensitization influences quality of life and comorbidities in patients with nasal polyposis

10.2500/ajra.2012.26.3792 · 2012 · External reference

Aspirin intolerance and allergy to house dust mites: important factors associated with development of severe asthma

10.1016/s1081-1206(10)61782-6 · 2004 · External reference

Emerging biomarkers beyond leukotrienes for the management of nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease

10.4168/aair.2022.14.2.153 · 2022 · External reference

Complementary participation of genetics and epigenetics in development of NSAID-exacerbated respiratory disease

10.4168/aair.2019.11.6.779 · 2019 · External reference

Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma

10.1513/annalsats.201310-354oc · 2014 · External reference

The eosinophil and airway remodelling in asthma

10.1111/j.1752-699x.2010.00192.x · 2010 · External reference

Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells

10.4049/jimmunol.177.7.4861 · 2006 · External reference

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma

10.1111/all.14221 · 2020 · External reference

Inflammatory and homeostatic roles of eosinophil subpopulations in chronic rhinosinusitis with nasal polyp pathogenesis

10.3389/fimmu.2025.1568541 · 2025 · External reference

Real-world outcomes on quality-of-life improvement in patients with nasal polyposis treated with mepolizumab. RINOSUR study

10.1016/j.otoeng.2024.08.001 · 2025 · External reference

Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial

10.1016/j.jaci.2021.08.030 · 2022 · External reference

Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease

2015 · External reference

Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab

10.1016/j.jaip.2016.12.013 · 2017 · External reference

Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: A randomized comparative trial

10.1016/j.jaip.2023.04.033 · 2023 · External reference

Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease

10.1183/13993003.01335-2022 · 2023 · External reference

Global initiative for asthma guidelines 2024: An update

10.1007/s13312-024-3260-7 · 2024 · External reference

EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity

10.1111/j.1398-9995.2007.01409.x · 2007 · External reference

NSAID-exacerbated respiratory disease (NERD): From pathogenesis to improved care

10.3389/fphar.2020.01147 · 2020 · External reference

Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity

10.1111/j.1365-2222.2005.02261.x · 2005 · External reference

Classification of reactions to nonsteroidal antiinflammatory drugs

10.1016/j.iac.2012.10.008 · 2013 · External reference

VAS--visual analog scale

10.4045/tidsskr.13.1145 · 2014 · External reference

Psychometric validity of the 22-item sinonasal outcome test

10.1111/j.1749-4486.2009.01995.x · 2009 · External reference

Development of the asthma control test: a survey for assessing asthma control

10.1016/j.jaci.2003.09.008 · 2004 · External reference

Key recommendations for primary care from the 2022 global initiative for asthma (GINA) update

10.1038/s41533-023-00330-1 · 2023 · External reference

Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease

10.1016/j.jaci.2021.05.043 · 2021 · External reference

Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma

10.1016/j.rmed.2013.03.014 · 2013 · External reference

Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

10.1016/s0140-6736(24)00852-3 · 2024 · External reference

Biologics in severe asthma: a state-of-the-art review

10.1183/16000617.0088-2024 · 2025 · External reference

Efficacy and safety of biologics for chronic rhinosinusitis with nasal polyps: a meta-analysis of real-world evidence

10.1111/all.16499 · 2025 · External reference

Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial

10.1111/bcp.16087 · 2024 · External reference

Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

10.1016/s2213-2600(21)00097-7 · 2021 · External reference

Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature

10.1016/j.jaci.2014.08.020 · 2015 · External reference